Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone65-6236-3388
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.70 million
Profitability
Miscellaneous
Employees168
OptionableOptionable
Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions
What is Wave Life Sciences' stock symbol?
Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."
How were Wave Life Sciences' earnings last quarter?
Wave Life Sciences Ltd (NASDAQ:WVE) released its quarterly earnings data on Friday, November, 9th. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.26) by $0.02. The company earned $4.49 million during the quarter, compared to analyst estimates of $5.36 million. Wave Life Sciences had a negative net margin of 1,114.49% and a negative return on equity of 112.13%. View Wave Life Sciences' Earnings History.
When is Wave Life Sciences' next earnings date?
What price target have analysts set for WVE?
5 brokerages have issued 12-month price targets for Wave Life Sciences' stock. Their forecasts range from $49.00 to $65.00. On average, they anticipate Wave Life Sciences' share price to reach $58.20 in the next twelve months. This suggests a possible upside of 54.8% from the stock's current price. View Analyst Price Targets for Wave Life Sciences.
What is the consensus analysts' recommendation for Wave Life Sciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences.
What are Wall Street analysts saying about Wave Life Sciences stock?
Here are some recent quotes from research analysts about Wave Life Sciences stock:
- 1. According to Zacks Investment Research, "WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. " (1/26/2019)
- 2. HC Wainwright analysts commented, "We value $49/share based on a risk-adjusted, sum-of-parts DCF analysis: beta of 0.69, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 6.6%, and tax rate of 15% beginning in FY 2027. We value $3/share, respectively, which together account for roughly 90% of our target with the remainder derived from FTD and ALS expected to enter the clinic during 2019. Risks to our target include: commercial, reimbursement, regulatory, along with clinical and manufacturing." (12/10/2018)
Has Wave Life Sciences been receiving favorable news coverage?
Media headlines about WVE stock have trended somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Wave Life Sciences earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Wave Life Sciences' key competitors?
Some companies that are related to Wave Life Sciences include TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Evotec (EVTCY), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT) and Ligand Pharmaceuticals (LGND).
Who are Wave Life Sciences' key executives?
Wave Life Sciences' management team includes the folowing people:
- Dr. Paul B. Bolno, Pres, CEO & Director (Age 45)
- Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 41)
- Dr. Chandra Vargeese, Sr. VP of Drug Discovery (Age 58)
- Mr. Keith Regnante, Chief Financial Officer (Age 49)
- Mr. Kyle B. Moran, Sr. VP of Operations & Bus. Analytics (Age 48)
Who are Wave Life Sciences' major shareholders?
Wave Life Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.27%), BB Biotech AG (4.97%), Northern Trust Corp (0.77%), Geode Capital Management LLC (0.66%), D. E. Shaw & Co. Inc. (0.43%) and WS Management Lllp (0.27%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Masaharu Tanaka, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.
Which major investors are selling Wave Life Sciences stock?
WVE stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Millennium Management LLC, WS Management Lllp, Bailard Inc., New York State Common Retirement Fund, Northern Trust Corp and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.
Which major investors are buying Wave Life Sciences stock?
WVE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., BB Biotech AG, D. E. Shaw & Co. Inc., Geode Capital Management LLC, Wexford Capital LP, Bank of America Corp DE, Rhumbline Advisers and Virtus ETF Advisers LLC. View Insider Buying and Selling for Wave Life Sciences.
How do I buy shares of Wave Life Sciences?
Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Wave Life Sciences' stock price today?
One share of WVE stock can currently be purchased for approximately $37.60.
How big of a company is Wave Life Sciences?
Wave Life Sciences has a market capitalization of $1.11 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe.
What is Wave Life Sciences' official website?
How can I contact Wave Life Sciences?
Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]
MarketBeat Community Rating for Wave Life Sciences (NASDAQ WVE)
MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
